All In MedTech

FDA Clearance Tracker · P120005-S091

G5 Mobile Continuous Glucose Monitoring System, G6 Continuous Glucose Monitoring System, G7 Continuous Glucose Monitorin

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 9, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P120005-S091
Device name
G5 Mobile Continuous Glucose Monitoring System, G6 Continuous Glucose Monitoring System, G7 Continuous Glucose Monitorin
Applicant
Dexcom, Inc.
Applicant location
San Diego, CA
Received
Nov 15, 2023
Decided
Jan 9, 2024
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P120005

Device type

Device class
Class III

Every decision under product code MDS

FDA's approval statement

As written in FDA's record.

Approval for updates to the protocol (PTL901895, V006), including addition of the Dexcom G7 CGM.

Source documents

Other decisions for Dexcom, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.